Patents by Inventor Thierry Boon-Falleur

Thierry Boon-Falleur has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR IDENTIFYING INDIVIDUALS SUFFERING FROM A CELLULAR ABNORMALITY SOME OF WHOSE ABNORMAL CELLS PRESENT COMPLEXES OF HUMAN LEUKOCYTE ANTIGEN TYROSINASE DERIVED PEPTIDES, AND METHODS FOR TREATING SAID INDIVIDUALS
    Patent number: 6669946
    Abstract: The invention relates to complexes of human leukocyte antigen molecules and tyrosinase derived peptides SEQ ID NO: 2, on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.
    Type: Grant
    Filed: December 11, 2001
    Date of Patent: December 30, 2003
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon-Falleur, Vincent Brichard, Aline Van Pel, Etienne De Plaen, Pierre Coulie, Jean-Christope Renauld, Thomas Wölfel, Bernard Lethe
  • Isolated peptides which bind to HLA-B35 molecules, larger peptides which contain these, nucleic acid molecules encoding peptides, and uses thereof
    Patent number: 6667037
    Abstract: The invention relates to peptides which bind to HLA-B35 molecules, leading to recognition and lysis of the resulting complexes by cytolytic T cells. Also a part of the invention are nucleic acid molecules which encode these peptides, and uses of each of these. The molecules are derived, in some cases, from tyrosinase, and portions of the tyrosinase molecule and portions of nucleic acid molecules which encode tyrosinase are also a part of the invention.
    Type: Grant
    Filed: October 9, 1998
    Date of Patent: December 23, 2003
    Assignees: Ludwig Institute for Cancer Research, Universite de Liege
    Inventors: Annie Ooms, Gérard De Giiovanni, Sandra Morel, Benoît Van Den Eynde, Thierry Boon-Falleur
  • Isolated peptides which bind to HLA-Cw6 molecules and uses thereof
    Publication number: 20030228308
    Abstract: A peptide, previously identified as a binding partner of HLA-Cw3 and Cw16, has now been found to bind to HLA-Cw6. The therapeutic and diagnostic ramifications of this are the subject of this invention, as are various products obtained in the course of the development of the invention.
    Type: Application
    Filed: June 5, 2002
    Publication date: December 11, 2003
    Inventors: Yi Zhang, Catia Traversari, Thierry Boon-Falleur, Pierre Van der Bruggen
  • Isolated peptides which bind to HLA-B18 molecules and uses thereof
    Publication number: 20030228325
    Abstract: A peptide, previously identified as a binding partner of HLA-B44, has now been found to bind to HLA-B18 forming a T cell epitope. The therapeutic and diagnostic ramifications of this are the subject of this invention, as are various products obtained in the course of the development of the invention.
    Type: Application
    Filed: June 5, 2002
    Publication date: December 11, 2003
    Inventors: Janine Bilsborough, Erwin Schultz, Christophe Panichelli, Thierry Boon-Falleur, Pierre Van der Bruggen
  • Method for treating subjects by using BAGE tumor rejection antigen precursors or tumor rejection antigens
    Patent number: 6638512
    Abstract: A family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as BAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as BAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigen precursor molecules are described.
    Type: Grant
    Filed: August 25, 1999
    Date of Patent: October 28, 2003
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Pascale Bo{haeck over (e)}l, Claude Wildmann, Thierry Boon-Falleur, Pierre van der Bruggen, Pierre Coulie, Jean-Christophe Renauld
  • MAGE-3 peptides presented by HLA class ll molecules
    Publication number: 20030170792
    Abstract: The invention describes HLA class II binding peptides encoded by the MAGE-3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the MAGE-3 gene.
    Type: Application
    Filed: June 12, 2002
    Publication date: September 11, 2003
    Inventors: Pascal Chaux, Vincent Stroobant, Thierry Boon-Falleur, Pierre van der Bruggen, Kris Thielemans, Jurgen Corthals
  • Isolated nucleic acid molecule coding for tumor rejection antigen precursors MAGE-C1 and MAGE-C2 and uses thereof
    Publication number: 20030170256
    Abstract: The invention relates to isolated nucleic acid molecules which code for antigens expressed by tumor cells which maybe recognized by cytotoxic T cells, leading to lysis of the tumor cells which express it. This invention also relates to vectors which are designed to encode the antigen expressed by tumor cells and also to cells transfected by the nucleic acid molecules or vectors which comprise the nucleic acid molecules. Various therapeutic and diagnostic uses arising out of the properties of the nucleic acid molecules and the antigens for which these code are also part of this invention.
    Type: Application
    Filed: June 4, 2002
    Publication date: September 11, 2003
    Inventors: Sophie Lucas, Charles De Smet, Thierry Boon-Falleur
  • Isolated molecules which complex with HLA-Cw*16 molecules, and uses thereof
    Publication number: 20030166837
    Abstract: The invention involves the identification of peptides which complex with HLA-Cw*16 molecules, and which may then provoke lysis of the cells to which they bind, by cytolytic T cells. Diagnostic and therapeutic uses are described.
    Type: Application
    Filed: May 23, 2002
    Publication date: September 4, 2003
    Inventors: Pierre van der Bruggen, Etienne DePlaen, Thierry Boon-Falleur
  • Isolated GAGE-7B and 8 proteins
    Publication number: 20030157651
    Abstract: The invention relates to new members of the GAGE family referred to as GAGE-7B and GAGE-8. There are differences between these two molecules and the previously described members of the GAGE family on the genomic DNA, complementary DNA, and amino acid level.
    Type: Application
    Filed: October 16, 2002
    Publication date: August 21, 2003
    Inventors: Olivier De Backer, Benoit Van den Eynde, Thierry Boon-Falleur
  • Methods for diagnosing a disorder by assaying for MAGE-3
    Patent number: 6599699
    Abstract: The invention relates to nucleic acid molecules which code for the tumor rejection antigen precursor MAGE-3. Also disclosed are vectors, cell lines, and so forth, which utilize the nucleic acid molecule, and optionally, molecules coding for human leukocyte antigen HLA-A1. Uses of these materials in therapeutic and diagnostic contexts are also a part of the invention.
    Type: Grant
    Filed: May 17, 1999
    Date of Patent: July 29, 2003
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Béatrice Guagler, Benoít Van den Eynde, Pierre van den Bruggen, Thierry Boon-Falleur
  • Method for determining BAGE expression
    Publication number: 20030138854
    Abstract: A family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as BAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as BAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigen precursor molecules are described.
    Type: Application
    Filed: February 20, 2002
    Publication date: July 24, 2003
    Inventors: Pascale Boel, Claude Wildmann, Thierry Boon-Falleur, Pierre van der Bruggen, Pierre Coulie, Jean-Christophe Renauld
  • Methods for treating a disorder by using Mage-3 or Mage-3 related materials
    Patent number: 6565857
    Abstract: The invention relates to nucleic acid molecules which code for the tumor rejection antigen precursor MAGE-3. Also disclosed are vectors, cell lines, and so forth, which utilize the nucleic acid molecule, and optionally, molecules coding for human leukocyte antigen HLA-A1. Uses of these materials in therapeutic and diagnostic contexts are also a part of the invention.
    Type: Grant
    Filed: September 23, 1999
    Date of Patent: May 20, 2003
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Benoit van den Eynde, Pierre van den Bruggen, Thierry Boon-Falleur
  • RECOMBINANT ADENOVIRAL VECTORS FOR HUMAN TUMOUR GENE THERAPY
    Publication number: 20030082150
    Abstract: A method for treating human tumours by gene therapy is disclosed. In particular, defective recombinant viruses with a sequence coding for a human tumour-specific antigen, and the use thereof for treating or preventing human tumours, as well as producing specific cytotoxic T-cells (CTLs) in vitro or ex vivo, are disclosed. Pharmaceutical compositions comprising said viruses, particularly in injectable form, are also disclosed.
    Type: Application
    Filed: October 5, 1998
    Publication date: May 1, 2003
    Inventors: THIERRY BOON-FALLEUR, MARIE-THERESE DUFFOUR, HEDI HADDADA, CHRISTOPHE LURQUIN, MICHEL PERRICAUDET, CATHERINE UYTTENHOVE-GHESQUIERE, GUY WARNIER
  • Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-2 and uses thereof
    Patent number: 6552180
    Abstract: Isolated nucleic acid molecules are described, which have complements that hybridize to a nucleic acid molecule referred to as MAGE-2. The isolated nucleic acid molecules are expressed in some melanoma cells, as well as other types of cancer cells. The invention also relates to nucleic acid molecules which encode fragments of the proteins encoded by these nucleic acid molecules, and nucleic acid molecules which encode the ultimate product, the so-called tumor rejection antigens.
    Type: Grant
    Filed: May 26, 2000
    Date of Patent: April 22, 2003
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Béatrice Guagler, Benoit Van den Eynde, Pierre van den Bruggen, Thierry Boon-Falleur
  • MAGE-A3 peptides presented by HLA class II molecules
    Publication number: 20030049723
    Abstract: The invention describes HLA class II binding peptides encoded by the MAGE-A3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+ T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the MAGE-A3 gene.
    Type: Application
    Filed: May 18, 2001
    Publication date: March 13, 2003
    Inventors: Yi Zhang, Pascal Chaux, Thierry Boon-Falleur, Pierre van der Bruggen
  • Isolated, truncated nucleic acid which are members of the gage, and uses thereof
    Patent number: 6509172
    Abstract: The invention relates to new members of the GAGE family referred to as GAGE-7B and GAGE-8. There are differences between these two molecules and the previously described members of the GAGE family on the genomic DNA, complementary DNA, and amino acid level.
    Type: Grant
    Filed: September 30, 1998
    Date of Patent: January 21, 2003
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Olivier De Backer, Benoit Van den Eynde, Thierry Boon-Falleur
  • Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B families and uses thereof
    Publication number: 20020176865
    Abstract: The invention relates to isolated nucleic acid molecules which code for antigens expressed by tumor cells which maybe recognized by cytotoxic T cells, leading to lysis of the tumor cells which express it. This invention also relates to vectors which are designed to encode the antigen expressed by tumor cells and also to cells transfected by the nucleic acid molecules or vectors which comprise the nucleic acid molecules. Various therapeutic and diagnostic uses arising out of the properties of the nucleic acid molecules and the antigens for which these code are also part of this invention.
    Type: Application
    Filed: March 1, 2002
    Publication date: November 28, 2002
    Inventors: Sophie Lucas, Thierry Boon-Falleur
  • MAGE antigenic peptides which bind HLA-B35 and HLA-B44
    Publication number: 20020164654
    Abstract: The invention provides antigenic peptides derived from MAGE-A1 polypeptides and presented by HLA-B35 and HLA-B44 molecules. Antigenic peptides derived from MAGE-A3 polypeptides and presented by HLA-B35 molecules also are provided. Methods for diagnosis and treatment which involve the polypeptides also are provided.
    Type: Application
    Filed: January 19, 2001
    Publication date: November 7, 2002
    Inventors: Rosalie Luiten, Thierry Boon-Falleur, Pierre Van der Bruggen, Vincent Stroobant, Nathalie Demotte, Erwin Schultz
  • Isolated nucleic acid molecule coding for tumor rejection antigen precursors MAGE-C1 and MAGE-C2 and uses thereof
    Patent number: 6475783
    Abstract: The invention relates to isolated nucleic acid molecules which code for antigens expressed by tumor cells which maybe recognized by cytotoxic T cells, leading to lysis of the tumor cells which express it. This invention also relates to vectors which are designed to encode the antigen expressed by tumor cells and also to cells transfected by the nucleic acid molecules or vectors which comprise the nucleic acid molecules. Various therapeutic and diagnostic uses arising out of the properties of the nucleic acid molecules and the antigens for which these code are also part of this invention.
    Type: Grant
    Filed: April 24, 1998
    Date of Patent: November 5, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Sophie Lucas, Charles De Smet, Thierry Boon-Falleur
  • Isolated nucleic acid molecule encoding peptides which form complexes with MHC molecules HLA-Cw*1601 and uses thereof
    Patent number: 6465184
    Abstract: A family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as BAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as BAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigen precursor molecules are described.
    Type: Grant
    Filed: November 8, 1999
    Date of Patent: October 15, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Pascale Bo{haeck over (e)}l, Claude Wildmann, Thierry Boon-Falleur, Pierre van der Bruggen, Pierre Coulie, Jean-Christophe Renauld